A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease | Completed
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
SHIELD-1
Trial Source

Health Conditions
  • Crohn's Disease
Completed
Recruitment Status
NCT01277666
Primary Trial ID Number
Summary
This is a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A as compared to placebo over 12 weeks in adult subjects with moderately-to-severely active Crohn's disease. Efficacy will be assessed by proportion of subjects achieving response, defined as a decrease in Crohn's Disease Activity Index (CDAI) score of at least 100 points (clinical response). Clinical remission (CDAI score less than 150 points) will be evaluated as a key secondary endpoint. Safety will be assessed by recording of adverse events, clinical laboratory parameters, vital signs and electrocardiogram (ECG). Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 version 2 (SF-36v2), EQ-5D and Work Productivity and Activity Impairment-CD (WPAI-CD) and receipt of disability.
Primary Outcome Measures
  • Proportion of subjects achieving clinical response; 12 weeks
Secondary Outcome Measures
  • Proportion of subjects in clinical remission; 12 weeks; Proportion of subjects achieving clinical response at other time points; 8 and 12 weeks; Proportion of subjects in clinical remission at other time points; 8 and 12 weeks; Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score; 12 weeks; Incidence of adverse events or serious adverse events; 12 weeks
Research Question
  • This is a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A as compared to placebo over 12 weeks in adult subjects with moderately-to-severely active Crohn's disease. Efficacy will be assessed by proportion of subjects achieving response, defined as a decrease in Crohn's Disease Activity Index (CDAI) score of at least 100 points (clinical response). Clinical remission (CDAI score less than 150 points) will be evaluated as a key secondary endpoint. Safety will be assessed by recording of adverse events, clinical laboratory parameters, vital signs and electrocardiogram (ECG). Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 version 2 (SF-36v2), EQ-5D and Work Productivity and Activity Impairment-CD (WPAI-CD) and receipt of disability.
Design Type
Sorry, this information is not available
Ethics Approval
Sorry, this information is not available
Publications
Sorry, this information is not available
Countries of Recruitment
United States; Australia; Austria; Belgium; Canada; Czech Republic; Denmark; France; Germany; Hungary; Israel; Italy; Japan; Korea, Republic of; Netherlands; New Zealand; Norway; Poland; Slovakia; South Africa; Spain; Sweden; United Kingdom
Participant Sex
Both
Participant Age Range
18 Years to N/A
Participant Type
Sorry, this information is not available
Trial Sample Size
Sorry, this information is not available
Participant Inclusion Criteria
  • Inclusion Criteria:
  • - Male or female subjects aged 18 years or older
  • - Written informed consent
  • - Diagnosis of Crohn's disease for greater than 4 months duration with small bowel
  • and/or colonic involvement
  • - Confirmation of Crohn's disease established by visualisation of the gastrointestinal
  • tract within the 12 months prior to screening or by screening endoscopy at study
  • entry
  • - History of inadequate response and/or intolerance/adverse event leading to
  • discontinuation of either corticosteroids or immunosuppressants
  • - Moderately-to-severely active disease characterised by a CDAI score between 220 and
  • 450, inclusive, at Baseline
  • - Confirmation of current active Crohn's disease by screening endoscopy or inflammatory
  • biomarkers [elevated C-reactive protein (greater than upper limit of normal) plus
  • positive test for faecal calprotectin] at Screening
  • - Stable doses of permitted concomitant medications or having previously received, but
  • are not currently receiving, medications for Crohn's disease
  • - Demonstrated ability to comply with Crohn's disease symptom recording using the
  • interactive voice response system
  • - Females of child-bearing potential must be sexually inactive or commit to consistent
  • and correct use of a contraceptive method of birth control with a failure rate of
  • less than 1% for the duration of this study
  • Exclusion Criteria:
  • - If female: pregnant, has a positive pregnancy test or is breast-feeding
  • - Diagnosis of coeliac disease, follow a gluten-free diet to manage symptoms, or
  • positive test for coeliac disease
  • - Diagnosis of ulcerative or indeterminate colitis
  • - Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to
  • require surgery during the study period
  • - Bowel surgery, other than appendectomy, within 12 weeks prior to screen and/or has
  • surgery planned or deemed likely for Crohn's disease during the study period
  • - Extensive colonic resection, subtotal or total colectomy
  • - Presence of ileostomies, colostomies or rectal pouches
  • - Known fixed symptomatic stenoses
  • - History of more than 3 small bowel resections or diagnosis of short bowel syndrome
  • - Chronic use of narcotics for chronic pain defined as daily use of one or more doses
  • of narcotic containing medication
  • - Use of prohibited medications, including enteral feeding or elemental diet, within
  • their specified time frames
  • 1. Biologic use: Use of any biologic (tumour necrosis factor inhibitor or
  • natalizumab) within 8 weeks prior to screening
  • 2. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to
  • screening
  • 3. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate
  • mofetil within 4 weeks prior to screening
  • 4. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease
  • within 4 weeks prior to screening
  • 5. Use of rectal treatment with 5-ASA or corticosteroid enemas/suppositories within
  • 2 weeks prior to screening
  • 6. Use of tube or enteral feeding, elemental diet, or parenteral alimentation
  • within 2 weeks prior to screening
  • 7. Leukocytapheresis or granulocytapheresis within 2 weeks prior to screening
  • - Positive immunoassay for Clostridium difficile
  • - Known human immunodeficiency virus (HIV) infection
  • - Known varicella, herpes zoster, or other severe viral infection within 6 weeks of
  • screening
  • - Immunisation with a live vaccine within 4 weeks of screening, with the exception of
  • influenza vaccine
  • - Active or latent tuberculosis infection
  • - Current sepsis or infections requiring intravenous antibiotic therapy for more than 2
  • weeks
  • - Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of
  • liver disease including non-alcoholic steatohepatitis (NASH)
  • - Positive test for Hepatitis B or Hepatitis C antibody at screening
  • - Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450
  • milliseconds
  • - Concurrent illness or disability that may affect the interpretation of clinical data,
  • or otherwise contraindicates participation in this clinical study
  • - History or evidence of adenomatous colonic polyps that have not been removed
  • - History of evidence of colonic mucosal dysplasia
  • - Current evidence of, or has been treated for a malignancy within the past five years
  • (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or
  • any cancer in situ that has been resected)
  • - Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx
  • compound CCX282-B)
  • - Medical history of sensitivity to any of the components of GSK1605786A
  • - Use of any investigational product within 30 days prior to screening
Participant Exclusion Criteria
  • Inclusion Criteria:
  • - Male or female subjects aged 18 years or older
  • - Written informed consent
  • - Diagnosis of Crohn's disease for greater than 4 months duration with small bowel
  • and/or colonic involvement
  • - Confirmation of Crohn's disease established by visualisation of the gastrointestinal
  • tract within the 12 months prior to screening or by screening endoscopy at study
  • entry
  • - History of inadequate response and/or intolerance/adverse event leading to
  • discontinuation of either corticosteroids or immunosuppressants
  • - Moderately-to-severely active disease characterised by a CDAI score between 220 and
  • 450, inclusive, at Baseline
  • - Confirmation of current active Crohn's disease by screening endoscopy or inflammatory
  • biomarkers [elevated C-reactive protein (greater than upper limit of normal) plus
  • positive test for faecal calprotectin] at Screening
  • - Stable doses of permitted concomitant medications or having previously received, but
  • are not currently receiving, medications for Crohn's disease
  • - Demonstrated ability to comply with Crohn's disease symptom recording using the
  • interactive voice response system
  • - Females of child-bearing potential must be sexually inactive or commit to consistent
  • and correct use of a contraceptive method of birth control with a failure rate of
  • less than 1% for the duration of this study
  • Exclusion Criteria:
  • - If female: pregnant, has a positive pregnancy test or is breast-feeding
  • - Diagnosis of coeliac disease, follow a gluten-free diet to manage symptoms, or
  • positive test for coeliac disease
  • - Diagnosis of ulcerative or indeterminate colitis
  • - Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to
  • require surgery during the study period
  • - Bowel surgery, other than appendectomy, within 12 weeks prior to screen and/or has
  • surgery planned or deemed likely for Crohn's disease during the study period
  • - Extensive colonic resection, subtotal or total colectomy
  • - Presence of ileostomies, colostomies or rectal pouches
  • - Known fixed symptomatic stenoses
  • - History of more than 3 small bowel resections or diagnosis of short bowel syndrome
  • - Chronic use of narcotics for chronic pain defined as daily use of one or more doses
  • of narcotic containing medication
  • - Use of prohibited medications, including enteral feeding or elemental diet, within
  • their specified time frames
  • 1. Biologic use: Use of any biologic (tumour necrosis factor inhibitor or
  • natalizumab) within 8 weeks prior to screening
  • 2. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to
  • screening
  • 3. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate
  • mofetil within 4 weeks prior to screening
  • 4. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease
  • within 4 weeks prior to screening
  • 5. Use of rectal treatment with 5-ASA or corticosteroid enemas/suppositories within
  • 2 weeks prior to screening
  • 6. Use of tube or enteral feeding, elemental diet, or parenteral alimentation
  • within 2 weeks prior to screening
  • 7. Leukocytapheresis or granulocytapheresis within 2 weeks prior to screening
  • - Positive immunoassay for Clostridium difficile
  • - Known human immunodeficiency virus (HIV) infection
  • - Known varicella, herpes zoster, or other severe viral infection within 6 weeks of
  • screening
  • - Immunisation with a live vaccine within 4 weeks of screening, with the exception of
  • influenza vaccine
  • - Active or latent tuberculosis infection
  • - Current sepsis or infections requiring intravenous antibiotic therapy for more than 2
  • weeks
  • - Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of
  • liver disease including non-alcoholic steatohepatitis (NASH)
  • - Positive test for Hepatitis B or Hepatitis C antibody at screening
  • - Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450
  • milliseconds
  • - Concurrent illness or disability that may affect the interpretation of clinical data,
  • or otherwise contraindicates participation in this clinical study
  • - History or evidence of adenomatous colonic polyps that have not been removed
  • - History of evidence of colonic mucosal dysplasia
  • - Current evidence of, or has been treated for a malignancy within the past five years
  • (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or
  • any cancer in situ that has been resected)
  • - Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx
  • compound CCX282-B)
  • - Medical history of sensitivity to any of the components of GSK1605786A
  • - Use of any investigational product within 30 days prior to screening
Interventions
Drug; GSK1605786A; 500 mg twice daily, administered orally for 12 weeks; [GSK1605786A 500mg twice daily]; Drug; GSK1605786A; 500 mg once daily, administered orally for 12 weeks; [GSK1605786A 500mg once daily]; Drug; Placebo; Placebo capsules, administered orally for 12 weeks; [Placebo]
Design Details
Sorry, this information is not available
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Results Reporting
Sorry, this information is not available
Acronym
SHIELD-1
Scientific Title
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Secondary Trial Identifying Number
Sorry, this information is not available
Website
Sorry, this information is not available
Study Funded By
GlaxoSmithKline
Funder Type
Sorry, this information is not available
Study Sponsored By
GlaxoSmithKline
Study Also Sponsored By
Sorry, this information is not available
Primary Sponsor Type
Sorry, this information is not available
Secondary Sponsor Type
Sorry, this information is not available
Key Dates

Date of First Enrollment
Date Not Available
Recruitment End Date
Date Not Available
Trial End Date
Date Not Available
Date added to Registry

13 Jan 2011

Last Updated

09 Jan 2014

Date Record Refreshed on UKCTG

24 Jul 2015